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Differences in hormonal and renal vascular responses between
normotensive patients with autosomal dominant polycystic kidney
disease and unaffected family members
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Differences in hormonal and renal vascular responses between normo-
tensive patients with autosomal dominant polycystic kidney disease and
unaffected family members. We tested the hypothesis that overactivity of
the renal and systemic renin-angiotensin system is important to the
pathogenesis of hypertension in autosomal dominant polycystic kidney
disease (ADPKD), Up to 21 normotensive subjects with ADPKD and
creatinine clearance >70 ml/min/1.73 m2 were compared to 12 unaffected
controls from the same families. Blood pressure, serum chemistzy, sodium
excretion, plasma renin and serum aldosterone and atrial natriuretic
peptide (ANP) levels were measured at baseline, after acute sodium
depletion, and after chronic higher sodium intake with and without
enalapril. Effective renal plasma flow was measured by paraaminohippu-
rate clearance in the higher sodium state, before and during an intrave-
nous infusion of angiotensin II at 3 ng/kg/min. This was to test whether, by
analogy to non-modulating essential hypertension, renal blood flow would
fall to a lesser extent in the ADPKD subjects. The groups were compa-
rable at baseline apart from a higher supine mean arterial pressure in the
ADPKD group (median 91 vs. 81 mm Hg, P = 0.002). There were no
significant differences between ADPKD and control subjects in blood
pressure or hormonal response to sodium depletion. During chronically
higher sodium intake, serum ANP was significantly higher (median 130 vs.
81 ng/liter, P = 0.0006) and plasma renin tended to be higher (median 20.5
vs. 13.5, P 0.08) in ADPKD than in control subjects. The ADPKD group
had a higher renal vascular resistance (median 7420 vs. 5915
dyn sec cm5, P = 0.009) before angiotensin, but tended to have a lower
percentage rise in resistance during angiotensin (median 31.5 vs. 46, P
0.14). The percent fall in effective renal plasma flow during angiotensin
was lower in the ADPKD subjects (17 vs. 23, P = 0.04) and renal plasma
flow fell by <120 ml/min/1,73 m2 in 8 of 13 with ADPKD versus 2 of 10
controls (P = 0.06). The relative insensitivity of the renal vasculature to
exogenous angiotensin II in normotensive subjects with ADPKD is
consistent with down-regulation of receptors due to tonically increased
intrarenal angiotensin levels. Given the higher blood pressure and ANP
levels, the plasma renin values were also inappropriately high in the
ADPKD subjects. We conclude that increased intrarenal and possibly
systemic renin-angiotensin system activity precedes and may contribute to
the development of hypertension in ADPKD.
Hypertension is common in patients with autosomal dominant
polycystic kidney disease (ADPKD). The prevalence of arterial
pressure greater than 150/90 in patients with ADPKD and pre-
served renal function has been estimated variously as 33 and 59%
[1, 2]. Children affected by ADPKD have been found to have
higher blood pressure than age matched unaffected controls [3].
Hypertension in ADPKD has been associated with a more rapid
decline in renal function [4, 5] and with left ventricular hypertro-
phy [6], a known risk factor for cardiovascular death [7]. An
understanding of the pathogenesis of hypertension in ADPKD is
therefore important and should help in choosing rational inter-
ventions to prevent or control the adverse consequences of the
higher blood pressure.
Hypertensive ADPKD patients have greater renal volume and
proportion of renal parenchymal cystic involvement than normo-
tensive ADPKD patients with similar renal function [2], ADPKD
kidneys show marked focal alteration in vascular architecture [8,
9] and immunohistochemical evidence of increased renin granules
[10]. It has been proposed that overactivity of the renin-angioten-
sin system is important to the pathogenesis of hypertension in
ADPKD [11—15]. It is possible that cyst induced alteration of
renal vessels leads to focal areas of renal ischemia with resultant
intrarenal renin-angiotensin activity inappropriate to systemic
hemodynamics and body sodium balance.
Williams, Hollenberg and others described a distinct subset of
patients with essential hypertension characterized by higher cir-
culating renin values and a failure of salt intake to modulate the
response of renal blood flow and adrenal aldosterone secretion to
angiotensin II [16—19]. It has been suggested that the renal defect
is due to a tonic overproduction of intrarenal renin and angio-
tensin [171, a situation which parallels the proposed defect in
ADPKD.
We compared normotensive patients with ADPKD who were
not in renal failure to normotensive family matched controls
under conditions of acute salt deprivation and chronic higher salt
intake to determine whether there was evidence for tonic intra-
renal angiotensin II overproduction or systemic renin or aldoste-
rone excess. We also compared the level and responses of atrial
natriuretic peptide (ANP) in the same patients since others have
variously documented higher or unchanged levels of ANP in
ADPKD [11, 13, 20].
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Subjects with a measured creatinine clearance >70 mI/min/1.73
were selected from a registry of families with ADPKD taking
part in an ongoing study of the condition [21]. Two groups of
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subjects were studied: those affected by ADPKD without hyper-
tension and unaffected normotensive controls from the same
families. The diagnosis of ADPKD was generally made by ultra-
sound as previously described [21]. Persons aged greater than 30
years who were ultrasound negative or those under 30 years with
negative genetic marker studies were considered unaffected.
Subjects were considered normotensive if they had not taken
medication for hypertension, the mean of three systolic readings
was less than 140 mmHg, and the mean of three diastolic readings
was less than 90 mm Hg at baseline. All medications that might
interfere with the study (such as oral contraceptives or nonsteroi-
dal anti-inflammatory drugs) were discontinued at least two weeks
prior to study. Pregnancy was excluded by history and urine
pregnancy test when appropriate. Informed consent was obtained
from all participants and the protocol was approved by the
Human Investigation Committee of Memorial University of New-
foundland.
The subjects were studied as outpatients. On the first day the
subjects attended the clinic with a 24-hour urine collection made
while taking their usual diet. Height and weight were measured.
They were then placed supine and after one-hour blood pressure
was measured in triplicate by mercury sphygmomanometer. A
blood sample was taken for serum sodium, potassium, chloride,
bicarbonate, urea, creatinine, calcium, inorganic phosphate, albu-
min, osmolality, hematocrit, renin, aldosterone and ANP. Plasma
active renin protein, serum aldosterone and atrial natriuretic
peptide were assayed by standard commercially available radio-
immunoassay kits available from ERIA Diagnostic Pasteur
(France), Diagnostics Products Corporation (Los Angeles, Cali-
fornia, USA), and INCSTAR Corporation (Stillwater, Minnesota,
USA), respectively. Blood pressure was again measured in tripli-
cate after the subjects had been standing for 15 minutes. The
subjects then followed a diet containing 10 mmol sodium for a 24
hour period. Oral furosemide in three doses to a total of 1.5 mg/kg
or 120 mg was taken during the same day and a 24-hour urine
collection was performed. On the following day the blood pres-
sure was measured after the subjects had been supine for 30
minutes and again after they had been upright for 15 minutes.
Body weight was recorded and a blood sample was taken after one
hour upright and was assayed for the same parameters as at
baseline.
The subjects then began a higher sodium diet for a ten day
period. They were either instructed to add salt to their food in a
measured amount or were given sodium chloride tablets. The
amount of added sodium was designed to increase the daily intake
to about 250 mmol. The ADPKD group added a median (range)
of 100 (0 to 100) and the controls 67 (0 to 150) mmol of sodium
daily. Their usual daily sodium intake was determined from the
average 24-hour sodium excretion in all 24-hour urine collections
made while consuming their usual diet. Two consecutive 24-hour
urine collections were made on the sixth and seventh days of the
higher salt diet to assess compliance. On the eighth day of the
higher salt diet the subjects attended the clinic and body weight
and standing blood pressure were recorded. The subjects were
then placed supine and the blood pressure was recorded one hour
later, at which time a blood sample was also taken and assayed for
the same parameters as at baseline.
We followed a protocol similar to Williams and Hollenberg [17]
to determine the effect of exogenous angiotensin II on effective
renal plasma flow while on a higher sodium diet. The effective
renal plasma flow was measured by paraaminohippurate (PAH)
clearance using a constant infusion technique [22]. A bolus of 8
mg/kg PAH was given intravenously and followed by a constant
infusion at 12 mg/mm. Blood samples were taken after 45 and 60
minutes of the infusion and the effective renal plasma flow was
calculated from these plateau concentrations and the infusion
rate. After 60 minutes of the PAH infusion a simultaneous
infusion of angiotensin II at 3 ng/kg/min was started. Blood
samples for PAH were obtained 30 and 45 minutes later and were
used to calculate the effective renal plasma flow while receiv-
ing angiotensin II. The expected normal response is a decrement
of >120 ml/min in effective renal plasma flow in response
to angiotensin II [17]. Renal vascular resistance (RVR)
(dyn sec cm5) was calculated according to the formula [12]:
RVR =
mean arterial pressure x (1 — hematocrit) X 79920
PAH clearance
Following the angiotensin II infusion the subjects were given 5
mg of enalapril by mouth. The higher sodium diet continued for
the following two days during which they also took enalapril 10
mg/day. On the final day of enalapril therapy the subjects returned
to the clinic for blood pressure measurements standing and after
one hour supine. A blood sample was taken supine and assayed
for the same parameters as at baseline.
Because of the small sample sizes data were summarized as
medians and ranges or as percentages. Comparison between
groups was made using the Mann Whitney-U test or Fishers exact
test as indicated. Pearson correlation coefficients were used to
examine associations between variables. Statistical significance
was declared at a two tailed P value of less than 0.05.
Patients
Twenty-one subjects with ADPKD and 12 controls were studied
at baseline. One subject with ADPKD failed to complete the
acute salt depletion protocol because of symptomatic hypoten-
sion. Sixteen subjects with ADPKD and 10 controls adhered to
the salt loading protocol. All of these received enalapril and had
blood pressure and hormone profiles determined. PAH clearance
could not be measured in 3 of the 16 ADPKD subjects because of
inadequate venous access. Table 1 shows the baseline character-
istics of the study groups. The subjects who had PAH clearances
performed did not differ from the study groups in general in terms
of any of these baseline characteristics. As shown in Table 1, the
supine and standing blood pressures were very similar within each
group separately. For clarity of presentation, unless otherwise
stated, these values have been averaged for each subject before
computing a group average blood pressure for all analyses. It is
noteworthy that, while the ADPKD subjects are normotensive,
their blood pressure is higher than that of the controls.
Results
Response to salt depletion
Equivalent sodium and volume depletion was observed in both
the ADPKD and control groups as determined by urinary sodium
and percentage weight loss during the salt depletion phase (Table
2, Fig. 1 and 2) The mean arterial pressure fell slightly in the
ADPKD group, but rose minimally in the controls. The levels of
renin, aldosterone and ANP changed in the expected directions
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and to a similar extent in both groups. The median plasma renin
was not significantly higher (Fig. 1), whereas the serum ANP was
significantly higher (Fig. 2) in the ADPKD group than in the
controls after this phase.
Response to higher salt intake
The median sodium excretion in both groups was very close to
the target value of 250 mmol/liter for the higher sodium phase
(Table 3, Figs. 1 and 2). Once again the ADPKD group had a
slightly higher blood pressure than the controls. The median
plasma renin in the ADPKD group was also higher, although the
difference did not quite reach statistical significance (Table 3, Fig.
1). The serum ANP was significantly higher in the ADPKD group
than in controls on the higher sodium diet (Table 3, Fig. 2). The
serum ANP levels did not correlate with creatinine clearance in
either group during usual or higher salt intake.
Response to enalapril
Surprisingly, the blood pressure felt to a lesser extent in the
ADPKD group than in controls when enalapril was taken with the
higher sodium intake (Table 4). The rise in renin and fall in
aldosterone and ANP after enalapril were not significantly differ-
ent between the ADPKD group and the controls. The median
renin and ANP values remained higher in the ADPKD group
after enalapril (Figs. I and 2).
EjJèctive renal plasma flow vascular resistance and response to
angiotensin II infusion
There was little difference in PAH clearance between ADPKD
subjects and controls prior to angiotensin II infusion (Table 5).
The ADPKD group had a significantly smaller fall in absolute and
proportional effective renal plasma flow than controls in response
to exogenous angiotensin 11. Effective renal plasma flow fell by
less than 120 ml/min in 8 of 13 ADPKD as opposed to 2 of 10
controls (P = 0.06). The percent fall in effective renal plasma flow
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Table 1. Baseline characteristics of the study groups
ADPKD
Male, female 10, 11
Median Range
30 16—54 32 18—46 NS
104 70—157 112 89—136 NS
159 100 —342 239 75—281 NS
68 46—103 75 48—102 NS
16 0.4—48 19 0—98 NS
Age years
Creatininc
clearance ml!
mm/i. 73 m2
24-Hour urine
sodium mmol
Weight kg
Plasma rcnin rig!
liter
Serum aldostcrooe
pmollli!er
Atrial natriuretic
peptide ng/liter
Supine mean
blood pressure
mm Hg
Standing mean
blood pressure
mm Hg
with angiotensin was inversely correlated with the mean arterial
Control
—
pressure on the higher salt intake (r = —0.35).
6
Renal vascular resistance was significantly higher and also
tended to rise to a smaller extent in the ADPKD group during
Median Range P angiotensin II infusion. On the higher salt diet the renal vascular
resistance before angiotensin did not correlate with plasma renin
(r = 0.009). However, the percentage change in renal vascular
resistance with angiotensin infusion was inversely correlated with
both plasma renin (r =
—0.33) and serum atrial natriuretic
peptide (r = —0.31). Angiotensin in the dose used for this study
had a similar pressor effect in both groups. The mean arterial
pressure increased by (median [range]) 7.7 [0.5 to 21.8] and 9 [3.3
160 34—490 120 17—372 NS to 21] mm Hg (P = NS) in the ADPKD and control groups,
respectively.
Discussion
102 37—271 80 27—159 NS
91 76—109 81 7397 0.002 The results of this study provide further support for the
hypothesis that tonic overproduction of renin in the kidney is
92 74—106 85 69—102 0.11 important in the pathogenesis of hypertension in ADPKD (Fig.
3). Our results are consistent with the notion that constantly high
intrarenal angiotensin levels impair the ability of the renal vascu-
lature to respond to exogenous low dose angiotensin. It has
previously been shown that high angiotensin IT levels lead to a
reduction in the number of available angiotensin binding sites on
vascular tissue [23]. The renal vascular defect in ADPKD appears
to be analogous to the proposed vascular defect identified by
Williams and Hollenberg et al [16, 17, 19] in a subset of high renin
essential hypertensive subjects. The effect of angiotensin convert-
ing enzyme (ACE) inhibitors on renal function in ADPKD is also
consistent with this hypothesis [14, 24]. In keeping with our data,
Watson and colleagues [24] found that ACE inhibitors caused
greater vasodilation in normotensive subjects with ADPKD than
in family matched controls. ACE inhibitors have been shown to
restore the sensitivity of the renal vasculature to exogenous
angiotensin in patients with non-modulating essential hyperten-
sion [18] probably by increasing the number of available angio-
tensin binding sites [23]. It is not yet known whether ACE
inhibitors would also restore the sensitivity of the renal vascula-
ture to angiotensin in ADPKD subjects. Although we did not find
a difference in the systemic blood pressure response to angioten-
sin Ti between the study groups the trend was to a smaller change
in the ADPKD subjects. Because of the small numbers, the minor
difference observed and the lack of statistical significance, we feel
that our observation does not supply definitive evidence as to
whether there is altered systemic vascular responsiveness to
angiotensin in ADPKD.
Although we argue that the renal vascular defect in ADPKD is
analagous to that described in nonmodulating essential hyperten-
sion, we do not imply that this defect necessarily has the same
genetic basis. in addition, nonmodulating essential hypertensive
subjects also show reduced adrenal responsiveness to acute salt
depletion after they have reached balance on a low salt intake
[16]. The mechanism of this adrenal defect is unclear, but unless
the underlying cause is common to ADPKD and nonmodulating
essential hypertension one would not necessarily expect to find a
reduction in aldosterone response to volume depletion in
ADPKD. In this study we found equivalent serum aldosterone
responses to acute volume depletion in the ADPKD and control
groups. However, this does not exclude the possibility of an
alteration in adrenal responsiveness because Rogacz, Williams
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Table 2. Responses to salt depletion in the study groups
ADPKD Control
Median Range Median Range P
24-Hour urinary sodium mmol
Percent weight change
Change in mean arterial
pressure mm Hg
Rise in plasma renin ng!liter
Rise in serum aldosterone
pmol/liter
Change in atrial natriuretic
peptide nglliter
296
—3.2
—1.5
91
1378
—33
169—435
—4.6 to +1
—9to +6
7—259
352—3861
—188 to + 11
304
—3.0
+1.7
88
1240
—35
114—378
—0.8 to —4.4
—7.6 to +11
12—690
191—4401
—0.4 to —96
NS
NS
NS
NS
NS
NS
and Hollenberg have shown that the normal enhancement of
adrenal responsiveness is not evident from plasma aldosterone
levels within 24 hours of salt restriction [241.
It is difficult to explain the smaller fall in blood pressure with
enalapril in the ADPKD group if their blood pressure is depen-
dent on excess renal angiotensin production. A close analysis of
the data fails to reveal any pattern to the change in supine versus
recumbent blood pressure values, any greater variance between
individual values within subjects in one group, or any tendency for
the results to be explained by differences between observers. We
note that serum ANP values remained higher in the ADPKD
subjects after enalapril. It may be that, since enalapril was only
taken for about 48 hours before the final blood pressure reading
and the subjects remained on the higher salt intake during that
time, there was insufficient time for the ADPKD group to excrete
any excess sodium accumulated as a result of higher renal
angiotensin production before enalapril.
The importance of matching for blood pressure when compar-
ing plasma renin values has been stressed by others [12]. We
attempted to compare normotensive subjects with ADPKD to
normotensive unaffected individuals from the same families in
order to match the blood pressures and to examine potentially
pathogenic mechanisms before hypertension was established. We
felt that it was important to identify perturbations that precede
150
140
130
120
110
100
90
8070
60
50
40
30
20
10
0
AD
Median
PKD
Range
Con
Median
trol
Range P
24-Hour urinary 248 146—326 247 170—347 NS
sodium mmol
Mean arterial 89 73—106 87 79—98 NS
pressure mm Hg
Plasma renin 20.5 3—66 13.5 3—26 .08
nglliter
Serum aldosterone 125 8—573 156 20—241 NS
pmol/liter
Atrial natriuretic 130 63—172 81 61—1 18 0.0006
peptide nglliter
and may cause the hypertension. Although our ADPKD subjects
were normotensive by currently accepted criteria, their blood
pressure was higher than their unaffected relatives, as has been
the case in other similar studies [13, 25]. ANP tends to suppress
renin release [26, 27], and serum ANP levels were higher in our
ADPKD subjects than in controls. Unlike Chapman and col-
leagues [12], who compared hypertensive subjects with ADPKD
to subjects with essential hypertension, we did not find plasma
P=NS
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120
110
100
90
80
7060
50
40
30
20
10
0
Fig. 1. Medianplasma renin values in the ADPKD (0) and control ()
groups at various points during the study.
P=0.0006
P=NS
P=NS
P=0.002
P=0.08
P=0.04
Baseline Salt deplete High salt Enalapril Baseline Salt deplete High salt Enalapril
Fig. 2. Median serum atrial natnuretic peptide values in the ADPKD (LI)
and control () groups at various points during the study.
Table 3. Responses to salt loading in the study groups
Abbreviation ADPKD is autosomal dominant polycystic kidney disease.
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Table 4. Responses to enalapril in the study groups
ADPKD
Median Range Median
Control
Range P
Change in mean blood —5.4 —18 to +1 —11 —15 to +1 0.04
pressure mm Hg
Change in plasma renin +33 —10 to +83 +28 —2to +184 NS
rig/liter
Change in serum
—14 —226 to +145 —11
—143 to +117 NS
aldosterone pmollliter
Change in atrial
—13 —73 to +237 —22
—35 to +14 NS
natriuretic peptide nglliter
Abbreviation ADPKD is autosomal dominant polycystic kidney disease.
Table 5. Responses to angiotensin II infusion in the study groups
ADPKD
Median Range Median
Control
Range P
Effective renal plasma flow 617 388—997 672 568—829 NS
before Ang II mI/mm/i. 73 m2
Effective renal plasma flow 514 354—849 537 404—691 NS
during Ang II mI/mm/i. 73 m2
Percent fall in effective 17 9—28 23 10—39 0.04
renal plasma flow with Ang II
Renal vascular resitance 7420 5266—14700 5915 4846—6742 0.009
before Ang II dyn sec cm5
Renal vascular resistance 9642 6384—17025 8654 6425—12871 NS
during Ang H dyn sec cm5
Percent rise in renal 31.5 16—57 46 19—105 0.14
vascular resistance with Ang II
Abbreviations are: ADPKD, autosomal dominant polycystic kidney disease; Ang II, angiotensin II.
renin values to be significantly elevated in the ADPKD subjects.
However, the fact that plasma renin values tended to be higher
rather than lower in our ADPKD subjects is noteworthy given
their higher blood pressure and ANP levels. The higher observed
renin values in our ADPKD subjects further support the hypoth-
esis that overactivity of the renin-angiotensin system is important
in the pathogenesis of hypertension in ADPKD.
A relatively higher serum ANP response to salt loading has
been demonstrated in hypertensive subjects with ADPKD [11].
Our data suggest that this elevation may precede the onset of
clinical hypertension, while Harrap et al [13] only found ANP
values to be minimally higher in normotensive ADPKD subjects
than controls. It is possible that the higher ANP levels represent
a compensatory response to enhanced activity of the renin-
angiotensin system, as ANP tends to antagonize the renal effects
of this system at several levels [26, 28]. Our study does not identify
the exact mechanism leading to the elevation in ANP. Plasma
volume has not been measurably higher in ADPKD subjects [11,
13]. It has been postulated that angiotensin mediated venocon-
striction leads to increased cardiac preload and that the resulting
atrial stretch leads to enhanced ANP release [29]. Left ventricular
hypertrophy is commonly seen in hypertensive subjects with
ADPKD [6] and left ventricular mass may be increased in children
and young adults with ADPKD [30]. Left ventricular hypertrophy
can be associated with increased serum ANP levels [31], possibly
due to diastolic dysfunction leading to atrial hypertension and
stretch.
The proposed pathogenesis of hypertension in ADPKD is
illustrated in Figure 3. The available evidence shows that circu-
—Z' artery
I vasoconstriction jBP
Fig. 3. The proposed pathogenetic mechanism for initiation of hypertension
in autosomal dominant polycystic kidney disease. ANP is atrial natriuretic
peptide. Aug II is angiotensin II. RBF is renal blood flow and RVR is
renal vascular resistance. BP implies systemic arterial blood pressure. Plus
signifies stimulation and minus inhibition of the indicated parameter.
lating renin levels are inappropriately elevated in hypertensive
[12] and probably normotensive subjects with ADPKD (this
study). Effective renal plasma flow tends to be lower, and renal
vascular resistance higher than expected prior to the onset of
/
/
®i Icardiac
/ preload?
vein
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hypertension in ADPKD [25, this study]. This hemodynamic
profile can be corrected by ACE inhibition [25]. That the response
to ACE inhibition is likely to be due to reduction in angiotensin
levels is supported by our data and the absence of compatible
changes in urinary excretion of prostaglandin metabolites and
kallikrein [25]. The stimulus for increased renal angiotensin
production in ADPKD may be local ischemia as indicated by the
abnormal renal vasculature [8, 9] and the correlation of blood
pressure with renal volume [2]. However, the fact that abnormal
renal hemodynamics and higher blood pressure may be present
prior to advanced renal structural changes [3, this study] requires
that one should be cautious in reaching such a conclusion. Serum
ANP levels may be elevated in hypertensive [11] and normoten-
sive (this study) subjects with ADPKD. The mechanism leading to
the increase in ANP is not entirely clear, but the ANP may serve
to partially antagonize the effects of the overactive renin-angio-
tensin system.
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